A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost

Criteria

Inclusion Criteria:

• Diagnosis of open-angle glaucoma or ocular hypertension

• No use of Lumigan® in the past 3 months

Exclusion Criteria:

• Received laser therapy, glaucoma surgery, cataract surgery, or other ocular surgery within the past 3 months